PL2234600T3 - Preparat przeciwciała - Google Patents

Preparat przeciwciała

Info

Publication number
PL2234600T3
PL2234600T3 PL08864416T PL08864416T PL2234600T3 PL 2234600 T3 PL2234600 T3 PL 2234600T3 PL 08864416 T PL08864416 T PL 08864416T PL 08864416 T PL08864416 T PL 08864416T PL 2234600 T3 PL2234600 T3 PL 2234600T3
Authority
PL
Poland
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
PL08864416T
Other languages
English (en)
Inventor
Michael Adler
Hanns-Christian Mahler
Christine Wurth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40532665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2234600(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2234600T3 publication Critical patent/PL2234600T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL08864416T 2007-12-21 2008-12-11 Preparat przeciwciała PL2234600T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07150335 2007-12-21
PCT/EP2008/067293 WO2009080541A1 (en) 2007-12-21 2008-12-11 Antibody formulation
EP08864416.6A EP2234600B1 (en) 2007-12-21 2008-12-11 Antibody formulation

Publications (1)

Publication Number Publication Date
PL2234600T3 true PL2234600T3 (pl) 2015-02-27

Family

ID=40532665

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08864416T PL2234600T3 (pl) 2007-12-21 2008-12-11 Preparat przeciwciała

Country Status (33)

Country Link
US (2) US20090162352A1 (pl)
EP (1) EP2234600B1 (pl)
JP (1) JP5881950B2 (pl)
KR (1) KR101247418B1 (pl)
CN (2) CN101896163A (pl)
AR (1) AR069788A1 (pl)
AU (1) AU2008340429C1 (pl)
BR (1) BRPI0820819B1 (pl)
CA (1) CA2708869C (pl)
CL (1) CL2008003788A1 (pl)
CO (1) CO6280464A2 (pl)
CR (1) CR11461A (pl)
CY (1) CY1115932T1 (pl)
DK (1) DK2234600T3 (pl)
EC (1) ECSP10010295A (pl)
ES (1) ES2511844T3 (pl)
HK (1) HK1214947A1 (pl)
HR (1) HRP20141249T1 (pl)
IL (1) IL206103A (pl)
MA (1) MA31984B1 (pl)
MX (1) MX2010006395A (pl)
MY (1) MY171841A (pl)
NZ (1) NZ585516A (pl)
PE (1) PE20091328A1 (pl)
PL (1) PL2234600T3 (pl)
PT (1) PT2234600E (pl)
RS (1) RS53551B1 (pl)
RU (1) RU2476238C2 (pl)
SI (1) SI2234600T1 (pl)
TW (1) TWI404728B (pl)
UA (1) UA101487C2 (pl)
WO (1) WO2009080541A1 (pl)
ZA (1) ZA201003907B (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414105T1 (de) * 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
US20080206229A1 (en) * 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
WO2005100560A1 (ja) * 2004-04-09 2005-10-27 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
EP1870458B1 (en) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
TW200718780A (en) * 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
CN101237890A (zh) * 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
AU2006256030B2 (en) * 2005-06-10 2012-06-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CL2007002057A1 (es) * 2006-07-13 2008-01-11 Chugai Pharmaceutical Co Ltd Diacuerpo anti-antigeno leucocitario humano (hla), usos del diacuerpo para preparar un medicamento util como inductor de muerte celular, supresor del crecimeinto celular o como agente antitumoral.
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013266987B2 (en) * 2009-09-11 2016-11-10 F. Hoffmann-La Roche Ag Highly concentrated pharmaceutical formulations comprising anti - CD20 antibody
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102686241A (zh) * 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
CN103059258A (zh) * 2012-12-07 2013-04-24 青岛文创科技有限公司 一种有机硅改性水性聚氨酯乳液
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103012731A (zh) * 2012-12-17 2013-04-03 青岛森淼实业有限公司 一种水性聚氨酯抗起球剂的制备方法
CN105209069B (zh) * 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
JP6407174B2 (ja) * 2013-03-15 2018-10-17 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 抗体の配合物および該配合物の使用
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN113350278B (zh) 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
CN105708811A (zh) * 2014-12-01 2016-06-29 西藏海思科药业集团股份有限公司 一种稳定的重组人抗cd20单克隆抗体的冻干制剂
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
SG10202108996PA (en) 2015-05-07 2021-09-29 Swedish Orphan Biovitrum Ag Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
JP2019532970A (ja) * 2016-10-24 2019-11-14 ノビミューン エスアー インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
WO2018096445A1 (en) * 2016-11-22 2018-05-31 Biocon Limited Stable formulation of recombinant humanized monoclonal antibody
CN108261391B (zh) 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261544B (zh) * 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
IL321935A (en) * 2017-10-19 2025-09-01 Hoffmann La Roche Treatment of CD20-positive B-cell lymphoma with obinutuzumab
CN112292146A (zh) * 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂
WO2020055360A2 (en) * 2018-08-10 2020-03-19 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The parenteral composition comprising carfilzomib
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US12257340B2 (en) * 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
WO2021068971A1 (en) * 2019-10-12 2021-04-15 Bio-Thera Solutions, Ltd. Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases
CN113081955B (zh) * 2020-01-09 2023-10-24 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的制剂
MX2022016232A (es) * 2020-06-19 2023-03-14 Agensys Inc Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN113855798A (zh) * 2021-09-30 2021-12-31 佛山汉腾生物科技有限公司 抗cd20的抗体制剂
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
WO2025037336A1 (en) * 2023-08-12 2025-02-20 Dr. Reddy's Laboratories Limited Pharmaceutical formulations of anti-cd 20 antibody and methods of preparing the same
WO2025037335A1 (en) * 2023-08-12 2025-02-20 Dr. Reddy's Laboratories Limited Formulations of anti-cd20 antibody
WO2026029570A1 (ko) * 2024-07-31 2026-02-05 삼성바이오에피스 주식회사 항-cd20 항체의 안정한 액상 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
IL161352A0 (en) * 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
PT2272868E (pt) * 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
PT1692182E (pt) * 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2632828C (en) * 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Antibodies against amyloid beta with glycosylation in the variable region
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
KR20080104160A (ko) * 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형

Also Published As

Publication number Publication date
JP5881950B2 (ja) 2016-03-09
HRP20141249T1 (xx) 2015-03-13
AR069788A1 (es) 2010-02-17
MY171841A (en) 2019-11-04
PE20091328A1 (es) 2009-09-03
JP2011506538A (ja) 2011-03-03
ECSP10010295A (es) 2010-07-30
TWI404728B (zh) 2013-08-11
NZ585516A (en) 2012-07-27
CO6280464A2 (es) 2011-05-20
CR11461A (es) 2010-08-16
RU2476238C2 (ru) 2013-02-27
CY1115932T1 (el) 2017-01-25
AU2008340429C1 (en) 2016-09-08
EP2234600B1 (en) 2014-08-20
MA31984B1 (fr) 2011-01-03
ZA201003907B (en) 2011-03-30
BRPI0820819A2 (pt) 2015-06-16
IL206103A0 (en) 2010-11-30
CN101896163A (zh) 2010-11-24
BRPI0820819B1 (pt) 2021-06-08
WO2009080541A1 (en) 2009-07-02
TW200934792A (en) 2009-08-16
CA2708869A1 (en) 2009-07-02
RU2010129481A (ru) 2012-01-27
ES2511844T3 (es) 2014-10-23
DK2234600T3 (da) 2014-09-08
CN105126099A (zh) 2015-12-09
US20090162352A1 (en) 2009-06-25
IL206103A (en) 2016-07-31
CA2708869C (en) 2016-06-28
SI2234600T1 (sl) 2014-12-31
PT2234600E (pt) 2014-09-25
KR101247418B1 (ko) 2013-03-25
RS53551B1 (sr) 2015-02-27
US20150353640A1 (en) 2015-12-10
CL2008003788A1 (es) 2010-02-19
AU2008340429B2 (en) 2015-02-12
AU2008340429A1 (en) 2009-07-02
UA101487C2 (en) 2013-04-10
MX2010006395A (es) 2010-07-01
KR20100087038A (ko) 2010-08-02
HK1214947A1 (zh) 2016-08-12
EP2234600A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
IL276622A (en) Antibody formulation
EP2077859A4 (en) ANTIBODY FORMULATION
ZA201003907B (en) Antibody formulation
IL193408A0 (en) Antibody formulation
IL202648A0 (en) Antibody formulations
ZA200909107B (en) Antibody formulations
EP2173163A4 (en) ANTIBODY FORMULATIONS
ZA201101343B (en) Novel antibody formulation
SI2146745T1 (sl) Penta-specifično protitelo
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
ZA200905636B (en) Stable antibody formulations
GB0708002D0 (en) Antibodies
ZA201004439B (en) Formulation
GB0720716D0 (en) Novel formulation
IL205073A0 (en) Anti-bst2 antibody
GB0718737D0 (en) Antibodies
GB0707463D0 (en) Formulation
GB0715723D0 (en) Formulation
GB0712972D0 (en) Formulation
EP2167635A4 (en) ANTIBODY FORMULATIONS
GB0812316D0 (en) Antibody
ZA200806951B (en) Homeopathy-based formulation
HK1133823A (en) Antibody formulation
GB0723900D0 (en) Lyophillised antigen composition
GB0723044D0 (en) Lyophillised antigen composition